Held, Thomas
Tessonnier, Thomas
Franke, Henrik
Regnery, Sebastian
Bauer, Lukas
Weusthof, Katharina
Harrabi, Semi
Herfarth, Klaus
Mairani, Andrea
Debus, Jürgen
Adeberg, Sebastian
Funding for this research was provided by:
Physician-Scientist Program of Heidelberg University, Faculty of Medicine
Deutsche Krebshilfe (70113618, 70113618)
Universitätsklinikum Heidelberg
Article History
Received: 27 March 2022
Accepted: 30 June 2022
First Online: 8 July 2022
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Ethics Committee of Heidelberg University (S-708/2018). Informed consent was obtained from all subjects involved in the study.
: Not applicable.
: JD reports grants from CRI The Clinical Research Institute, grants from View Ray Inc., grants from Accuray International, grants from Accuray Incorporated, grants from RaySearch Laboratories AB, grants from Vision RT limited, grants from Merck Serono GmbH, grants from Astellas Pharma GmbH, grants from Astra Zeneca GmbH, grants from Siemens Healthcare GmbH, grants from Solution Akademie GmbH, grants from Eromed PLC Surrey Research Park, grants from Quintiles GmbH, grants from Pharmaceutical Research Associates GmbH, grants from Boehringer Ingelheim Pharma GmbH Co, grants from PTW-Frieburg Dr. Pychlau GmbH, grants from Nanobiotix A.a., outside the submitted work. The other authors declare no conflict of interest. SA reports grants from Novocure Inc., Accuray International Sàrl, Merck Sharp&Dohme, Sanofi-Aventis GmbH and Merk Serono GmbH outside the submitted work. The other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.